ROCHESTER, Mich. , Nov. 28, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced that management will participate in the following upcoming investor
Q3 Revenue of $15.1 million , down 6% year-over-year and up 8% quarter-over-quarter Gross profit increased 4% year-over-year to $9.4 million as gross margins increased from 56% to 62% Generated $7.9 million in cash flow from operations during the first nine months of 2022 Repurchased 1.1 million
Virtual event takes place December 1, 2022 ROCHESTER, Mich. , Oct. 20, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced the third annual Innovate4Outcomes ®
ROCHESTER, Mich. , Oct. 19, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, will hold a conference call on Tuesday, November 8, 2022, at 4:30 p.m.
Analysis demonstrates effectiveness of OptimizeRx’s real-world evidence solution to identify patients suitable for a specialty therapy within a narrow timeframe ROCHESTER, Mich. , Oct. 11, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care
Innovative best-in-class technology solutions continue to offer HCPs a seamless prescribing experience within the EHR workflow ROCHESTER, Mich. , Sept. 20, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping
ROCHESTER, Mich. , Sept. 07, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, announced today that management will participate in the following September conferences on the
Analysis finds patent-pending real-world evidence solution successful in identifying HCPs with patients at risk of non-adherence due to unexpected cost. Proactive affordability messaging key for doctors and patients navigating Medicare coverage gaps ROCHESTER, Mich. , Aug.
Revenue Up 3% to $14.0 million , driven by new customer and program launches Increase in breadth and scope of brand deal size represents further momentum in the validation of our value proposition Generated $4.4 million in cash flow from operations during the first half of 2022 ROCHESTER, Mich.
Revenue Up 3% to $14.0 million , driven by new customer and program launches Increase in breadth and scope of brand deal size represents further momentum in the validation of our value proposition Generated $4.4 million in cash flow from operations during the first half of 2022 ROCHESTER, Mich.
